July 2nd 2024 Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer https://www.businesswire.com/news/home/20240628930127/en/Shorla-Oncology-Announces-FDA-Approval-for-TEPYLUTE-A-Novel-Formulation-to-Treat-Breast-and-Ovarian-Cancer?utm_campaign=shareaholic&utm_medium=linkedin&utm_source=socialnetwork
FDA Approves Tepylute for Breast and Ovarian Cancer TreatmentJuly 2nd 2024Read More FDA Approves Tepylute for Breast and Ovarian Cancer Treatment
FDA approves Shorla Oncology’s TEPYLUTE for cancer treatmentJuly 2nd 2024Read More FDA approves Shorla Oncology’s TEPYLUTE for cancer treatment
Sharon Cunningham & Orlaith Ryan are 2024 EY Entrepreneur Of The Year FinalistsApril 24th 2024Read More Sharon Cunningham & Orlaith Ryan are 2024 EY Entrepreneur Of The Year Finalists
FDA Considers SH-201 for Treating Certain Leukemias and CancersApril 22nd 2024Read More FDA Considers SH-201 for Treating Certain Leukemias and Cancers